Liaw YF - Search Results

1

Determinants for sustained HBeAg response to lamivudine therapy.

Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Chien RN, et al. Among authors: liaw yf. Hepatology. 2003 Nov;38(5):1267-73. doi: 10.1053/jhep.2003.50458. Hepatology. 2003. PMID: 14578866

2

Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion.

Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Chu CM, et al. Among authors: liaw yf. J Clin Microbiol. 2002 Jan;40(1):16-21. doi: 10.1128/JCM.40.1.16-21.2002. J Clin Microbiol. 2002. PMID: 11773086 Free PMC article.

3

Management of patients with chronic hepatitis B.

Liaw YF. Liaw YF. J Gastroenterol Hepatol. 2002 Apr;17(4):406-8. doi: 10.1046/j.1440-1746.2002.02736.x. J Gastroenterol Hepatol. 2002. PMID: 11982720 Review.

4

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Hsu YS, et al. Among authors: liaw yf. Hepatology. 2002 Jun;35(6):1522-7. doi: 10.1053/jhep.2002.33638. Hepatology. 2002. PMID: 12029639

5

Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women.

Yu MW, Yang YC, Yang SY, Chang HC, Liaw YF, Lin SM, Liu CJ, Lee SD, Lin CL, Chen PJ, Lin SC, Chen CJ. Yu MW, et al. Among authors: liaw yf. Hepatology. 2002 Jul;36(1):156-63. doi: 10.1053/jhep.2002.33897. Hepatology. 2002. PMID: 12085360

6

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD. Perrillo RP, et al. Among authors: liaw yf. Hepatology. 2002 Jul;36(1):186-94. doi: 10.1053/jhep.2002.34294. Hepatology. 2002. PMID: 12085364 Clinical Trial.

7

Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.

Peng CY, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, Chu CM, Liaw YF. Peng CY, et al. Among authors: liaw yf. Anticancer Res. 2002 Mar-Apr;22(2B):1265-71. Anticancer Res. 2002. PMID: 12168936

8

Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.

Chen YC, Sheen IS, Chu CM, Liaw YF. Chen YC, et al. Among authors: liaw yf. Gastroenterology. 2002 Oct;123(4):1084-9. doi: 10.1053/gast.2002.36026. Gastroenterology. 2002. PMID: 12360470

9

Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.

Liaw YF. Liaw YF. J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S333-7. doi: 10.1046/j.1440-1746.17.s3.23.x. J Gastroenterol Hepatol. 2002. PMID: 12472959 Review.

10

Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications.

Tsai SL, Sheen IS, Chien RN, Chu CM, Huang HC, Chuang YL, Lee TH, Liao SK, Lin CL, Kuo GC, Liaw YF. Tsai SL, et al. Among authors: liaw yf. J Biomed Sci. 2003 Jan-Feb;10(1):120-35. doi: 10.1007/BF02256004. J Biomed Sci. 2003. PMID: 12566993

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

554 results

Search Page